Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caffeinol
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Caffeinol is a combination drug consisting of caffeine and ethanol, primarily investigated for its neuroprotective and anticonvulsive properties. It has been studied as a potential treatment for acute ischemic stroke and traumatic brain injury. Its mechanism of action is believed to involve antagonism of N-methyl-D-aspartate (NMDA) receptors, with caffeine augmenting the anti-ischemic effects of NMDA receptor blockers. Preclinical studies have shown Caffeinol to reduce cortical damage and improve neurological outcomes, and it has advanced to pilot clinical trials in humans for acute ischemic stroke.
- Other names
- caffeine and ethanolcaffeine and alcohol
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Caffeinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caffeinol.